surpass cvot tirzepatide results In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx 💡 New insight in diabetes

Information on tirzepatides efficacy and safety has been primarily documented through case reports, clinical trials, and meta-analyses

Previous Response A medication that has already worked well and been tolerated may remain a practical choice

Second Natures peer-reviewed study published in JMIR Formative Research (2025) compared both medications within our programme: 3 Tirzepatide (Mounjaro) cohort (209 people): 22.1% average weight loss at 12 months 95.2% achieved at least 10% weight loss 83.7% achieved at least 15% weight loss Semaglutide (Wegovy) cohort (130 people): 17.1% average weight loss at 12 months 83.1% achieved at least 10% weight loss 56.2% achieved at least 15% weight loss Both cohorts exceeded clinical trial results, suggesting that comprehensive behavioural support enhances outcomes regardless of which medication you use

Now that I am starting to see the scale move, I am even more excited about my journey with Vitastir

Dual agonism may provide greater consistency of response across diverse patient populations by targeting multiple mechanisms simultaneously